Key Dates

Related Announcements

PAR-20-278 - NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the eligibility status of "Non-domestic (non-U.S.) components of U.S. Organizations" in Foreign Institutions under Eligible Applicants in PAR-20-278 "NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)".

The following text of Part 2. Full Text of Announcement, Section III. Eligibility Information, 1. Eligible Applicants, Foreign Institutions has been corrected (in italics):

Currently reads:

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

Should correctly read (italics):

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

All other aspects of PAR-20-278 are unchanged.

Inquiries

Please direct all inquiries to:

Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email: siemonc@nih.gov

Christopher Hatch, Ph.D.
National Cancer Institute (NCI) 
Telephone: 240-276-6454 
Email: hatchc@mail.nih.gov

Crystal Wolfrey 
National Cancer Institute (NCI)
Telephone: 240-276-6277 
Email: wolfreyc@mail.nih.gov